Information Provided By: 
Fly News Breaks for June 24, 2015
MDSO
Jun 24, 2015 | 07:16 EDT
Stifel sees several indications that Medidiata's downside risk may be limited, including increased adoption of its modules by biopharma trial sponsors and contract research organizations. The firm sees strong evidence of adoption of the company's products by clients and continues to keep the stock on its Select List. Stifel keeps a $65 price target and Buy rating on the name.
News For MDSO From the Last 2 Days
There are no results for your query MDSO
